Table 1.

Design of L-DOPA/TBZ trial in YAC128 mice

Group	Group name	Number of mice	Mouse genotype	Single dose (50 μl) (two per week)	Drug dosage (mg/kg)
1	WT-Ctrl	10 (5F, 5M)	WT	50 μl PBS	50 μl PBS
2	WT-DOPA	10 (7F, 3M)	WT	2.5 mg L-DOPA and 0.3 mg benserazide	100 L-DOPA and 12 benserazide
3	WT-DOPA/TBZ	10 (7F, 3M)	WT	2.5 mg L-DOPA, 0.3 mg benserazide, and 0.125 mg TBZ	100 L-DOPA, 12 benserazide, and 5 TBZ
4	YAC-Ctrl	9 (4F, 5M)	YAC128	50 μl PBS	50 μl PBS
5	YAC-DOPA	8 (4F, 4M)	YAC128	2.5 mg L-DOPA and 0.3 mg benserazide	100 L-DOPA and 12 benserazide
6	YAC-DOPA/TBZ	8 (4F, 4M)	YAC128	2.5 mg L-DOPA, 0.3 mg benserazide, and 0.125 mg TBZ	100 L-DOPA, 12 benserazide, and 5 TBZ

Six groups of mice were tested in our experiments. At 2 months of age, WT and YAC128 mice were divided into three groups each, and drug treatment was initiated. The group number, group name, number and genotype of mice in each group, and dose of single drug treatment (two/week) are shown for each group. Also shown is the estimated drug dosage in mg/kg. Ctrl, Control; F, female; M, male; YAC, YAC128.